NZ602710A - Use of novel pan-cdk inhibitors for treating tumors - Google Patents
Use of novel pan-cdk inhibitors for treating tumorsInfo
- Publication number
- NZ602710A NZ602710A NZ602710A NZ60271011A NZ602710A NZ 602710 A NZ602710 A NZ 602710A NZ 602710 A NZ602710 A NZ 602710A NZ 60271011 A NZ60271011 A NZ 60271011A NZ 602710 A NZ602710 A NZ 602710A
- Authority
- NZ
- New Zealand
- Prior art keywords
- treating tumors
- cdk inhibitors
- novel pan
- pyrimidin
- oxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102010014426A DE102010014426A1 (de) | 2010-04-01 | 2010-04-01 | Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren |
| PCT/EP2011/054733 WO2011120922A1 (de) | 2010-04-01 | 2011-03-28 | Verwendung neuer pan-cdk-inhibitoren zur behandlung von tumoren |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ602710A true NZ602710A (en) | 2014-05-30 |
Family
ID=43858236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ602710A NZ602710A (en) | 2010-04-01 | 2011-03-28 | Use of novel pan-cdk inhibitors for treating tumors |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20130210846A1 (enExample) |
| EP (1) | EP2552450A1 (enExample) |
| JP (1) | JP5816259B2 (enExample) |
| KR (1) | KR20130014678A (enExample) |
| CN (1) | CN102834100A (enExample) |
| AU (1) | AU2011234654B2 (enExample) |
| BR (1) | BR112012024422A2 (enExample) |
| CA (1) | CA2794996A1 (enExample) |
| CL (1) | CL2012002753A1 (enExample) |
| CR (1) | CR20120502A (enExample) |
| DE (1) | DE102010014426A1 (enExample) |
| DO (1) | DOP2012000260A (enExample) |
| EC (1) | ECSP12012198A (enExample) |
| MA (1) | MA34098B1 (enExample) |
| MX (1) | MX337722B (enExample) |
| NZ (1) | NZ602710A (enExample) |
| PH (1) | PH12012501945A1 (enExample) |
| SG (2) | SG183925A1 (enExample) |
| TN (1) | TN2012000469A1 (enExample) |
| UA (1) | UA108494C2 (enExample) |
| WO (1) | WO2011120922A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140135215A (ko) * | 2012-03-21 | 2014-11-25 | 바이엘 인텔렉쳐 프로퍼티 게엠베하 | 특정한 종양의 치료를 위한 (rs)-s-시클로프로필-s-(4-｛[4-｛[(1r, 2r)-2-히드록시-1-메틸프로필]옥시｝-5-(트리플루오로메틸)피리미딘-2-일]아미노｝페닐)술폭시미드의 용도 |
| US20160045496A1 (en) * | 2013-03-07 | 2016-02-18 | Bayer Pharma Aktiengesellschaft | Use of (rs)-s-cyclopropyl-s-(4--5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide for treatment of specific tumours |
| ES2734568T3 (es) * | 2013-03-13 | 2019-12-10 | Oncoceutics Inc | 7-Bencil-10-(2-metilbencil)-2,6,7,8,9,10-hexahidroimidazo[1,2-a]pirido[4,3-d]pirimidin-5(3H)-ona para su uso en el tratamiento de cáncer |
| WO2014173815A1 (en) * | 2013-04-23 | 2014-10-30 | Bayer Pharma Aktiengesellschaft | Use of (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5- (trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulphoximide for the treatment of specific tumours |
| EP3010902A1 (en) * | 2013-06-21 | 2016-04-27 | Bayer Pharma Aktiengesellschaft | Substituted benzylpyrazoles |
| WO2015071231A1 (de) * | 2013-11-14 | 2015-05-21 | Bayer Pharma Aktiengesellschaft | Kombinationen von (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluormethyl)pyrimidin-2-yl]amino}phenyl)sulfoximid zur behandlung von tumoren |
| CN109283263B (zh) * | 2017-07-21 | 2019-06-25 | 南京正大天晴制药有限公司 | 用于雷替曲塞合成质量控制的检测分析方法 |
| CN109283279B (zh) * | 2017-07-21 | 2019-11-01 | 南京正大天晴制药有限公司 | 通过高效液相色谱法分离测定雷替曲塞及其对映异构体的方法 |
| IL303237A (en) * | 2020-11-27 | 2023-07-01 | Anrui Biomedical Tech Guangzhou Co Ltd | Aminoheteroaryl kinase inhibitors |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4029650A1 (de) | 1990-09-19 | 1992-03-26 | Hoechst Ag | 2-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als fungizide |
| ES2253821T3 (es) | 1997-07-12 | 2006-06-01 | Cancer Research Technology Limited | Derivados de purina inhibidores de quinasa que depende de ciclina. |
| US6440965B1 (en) | 1997-10-15 | 2002-08-27 | Krenitsky Pharmaceuticals, Inc. | Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system |
| ES2270612T3 (es) | 1998-08-29 | 2007-04-01 | Astrazeneca Ab | Compuestos de pirimidina. |
| GB9824579D0 (en) * | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
| GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
| GB0016877D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
| IL159120A0 (en) | 2001-05-29 | 2004-05-12 | Schering Ag | Cdk inhibiting pyrimidines, production thereof and their use as medicaments |
| EP1483260A1 (de) | 2002-03-11 | 2004-12-08 | Schering Aktiengesellschaft | Cdk inhibitorische 2-heteroaryl-pyrimidine, deren herstellung und verwendung als arzneimittel |
| DE10349423A1 (de) | 2003-10-16 | 2005-06-16 | Schering Ag | Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
| DE102005062742A1 (de) * | 2005-12-22 | 2007-06-28 | Bayer Schering Pharma Ag | Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel |
| DE102006027156A1 (de) * | 2006-06-08 | 2007-12-13 | Bayer Schering Pharma Ag | Sulfimide als Proteinkinaseinhibitoren |
| EP1878726A1 (en) * | 2006-07-12 | 2008-01-16 | Bayer Schering Pharma Aktiengesellschaft | Substituted sulphoximines as Tie2 inhibitors and salts thereof, pharmaceutical compositions comprising the same, methods of preparing the same and uses of the same |
| EP2022785A1 (en) * | 2007-06-20 | 2009-02-11 | Bayer Schering Pharma Aktiengesellschaft | Alkynylpyrimidines as Tie2 kinase inhibitors |
| US20090203709A1 (en) * | 2008-02-07 | 2009-08-13 | Abbott Laboratories | Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor |
| EP2179991A1 (de) * | 2008-10-21 | 2010-04-28 | Bayer Schering Pharma Aktiengesellschaft | Sulfoximinsubstituierte Anilino-Pyrimidinderivate als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
-
2010
- 2010-04-01 DE DE102010014426A patent/DE102010014426A1/de not_active Withdrawn
-
2011
- 2011-03-28 NZ NZ602710A patent/NZ602710A/en not_active IP Right Cessation
- 2011-03-28 US US13/638,833 patent/US20130210846A1/en not_active Abandoned
- 2011-03-28 CN CN2011800166124A patent/CN102834100A/zh active Pending
- 2011-03-28 CA CA2794996A patent/CA2794996A1/en not_active Abandoned
- 2011-03-28 SG SG2012065819A patent/SG183925A1/en unknown
- 2011-03-28 SG SG10201502566SA patent/SG10201502566SA/en unknown
- 2011-03-28 BR BR112012024422A patent/BR112012024422A2/pt not_active IP Right Cessation
- 2011-03-28 WO PCT/EP2011/054733 patent/WO2011120922A1/de not_active Ceased
- 2011-03-28 AU AU2011234654A patent/AU2011234654B2/en not_active Ceased
- 2011-03-28 MX MX2012011427A patent/MX337722B/es active IP Right Grant
- 2011-03-28 JP JP2013501789A patent/JP5816259B2/ja not_active Expired - Fee Related
- 2011-03-28 MA MA35265A patent/MA34098B1/fr unknown
- 2011-03-28 EP EP11710224A patent/EP2552450A1/de not_active Withdrawn
- 2011-03-28 UA UAA201212233A patent/UA108494C2/uk unknown
- 2011-03-28 KR KR1020127025684A patent/KR20130014678A/ko not_active Ceased
- 2011-03-28 PH PH1/2012/501945A patent/PH12012501945A1/en unknown
-
2012
- 2012-09-27 TN TNP2012000469A patent/TN2012000469A1/en unknown
- 2012-10-01 EC ECSP12012198 patent/ECSP12012198A/es unknown
- 2012-10-01 CR CR20120502A patent/CR20120502A/es unknown
- 2012-10-01 CL CL2012002753A patent/CL2012002753A1/es unknown
- 2012-10-01 DO DO2012000260A patent/DOP2012000260A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP12012198A (es) | 2012-10-30 |
| MX337722B (es) | 2016-03-16 |
| AU2011234654A1 (en) | 2012-10-25 |
| TN2012000469A1 (en) | 2014-01-30 |
| AU2011234654B2 (en) | 2015-08-06 |
| PH12012501945A1 (en) | 2017-08-09 |
| EP2552450A1 (de) | 2013-02-06 |
| MX2012011427A (es) | 2013-03-05 |
| BR112012024422A2 (pt) | 2016-05-31 |
| DOP2012000260A (es) | 2013-03-31 |
| SG10201502566SA (en) | 2015-05-28 |
| MA34098B1 (fr) | 2013-03-05 |
| JP5816259B2 (ja) | 2015-11-18 |
| WO2011120922A1 (de) | 2011-10-06 |
| CN102834100A (zh) | 2012-12-19 |
| CL2012002753A1 (es) | 2013-01-18 |
| UA108494C2 (uk) | 2015-05-12 |
| JP2013523680A (ja) | 2013-06-17 |
| DE102010014426A1 (de) | 2011-10-06 |
| SG183925A1 (en) | 2012-10-30 |
| US20130210846A1 (en) | 2013-08-15 |
| CA2794996A1 (en) | 2011-10-06 |
| KR20130014678A (ko) | 2013-02-08 |
| CR20120502A (es) | 2012-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ602710A (en) | Use of novel pan-cdk inhibitors for treating tumors | |
| GEP201606532B (en) | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 | |
| MX2013007336A (es) | Compuestos de bi-heteroarilo como inhibidores de vps34. | |
| MX2014002208A (es) | Inhibidores de serina/treonina quinasa. | |
| PH12014501277A1 (en) | Kinase inhibitors | |
| PH12015501860B1 (en) | Dispiropyrrolidine derivative | |
| GEP20166432B (en) | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh | |
| TN2014000003A1 (en) | Fungicidal alkyl-substituted 2-[2-chloro-4-(4-chloro-phenoxy)-phenyl]-1-[1,2,4]triazol-1-yl-ethanol compounds | |
| AR087451A1 (es) | Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes | |
| BR112014005468A2 (pt) | derivados de aminopiridina para uso como moduladores de atividade quinase | |
| MX2015001246A (es) | Ibrutinib deuterado. | |
| PH12014500373A1 (en) | Amino quinazolines as kinase inhibitors | |
| MY169495A (en) | Pharmaceutical compositions | |
| EA024194B8 (ru) | Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы | |
| UA102289C2 (ru) | Гербициды, полученные из циклопентадиона | |
| NZ608448A (en) | Process for preparing pan-cdk inhibitors of the formula (i), and intermediates in the preparation | |
| PH12014501278A1 (en) | Kinase inhibitors | |
| EA201301136A2 (ru) | Новый способ синтеза (2e)-3-(3,4-диметоксифенил)проп-2-еннитрила, применение в синтезе ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей | |
| TN2014000391A1 (en) | Use of (rs)-s-cyclopropyl-s-(4-{[4-{[1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide for treating specific tumours | |
| MX2015006806A (es) | Procedimiento para preparar 4-(ciclopropilmetoxi)-n-(3,5-dicloro-1 -oxido-4-piridil)-5-metoxipiridina-2-carboxamida. | |
| EA201301235A1 (ru) | Новый способ синтеза 3-(2-бром-4,5-диметоксифенил)пропаннитрила и применение в синтезе ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей | |
| EA201301020A1 (ru) | Новый способ синтеза 3-(2-бром-4,5-диметоксифенил)пропаннитрила и применение в синтезе ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей | |
| WO2013074905A3 (en) | Compounds, compositions, pharmaceutical compositions, and methods of use | |
| UA68915U (ru) | Соединение 1,1'-(2"-бром-2"-хлорэтенил)-бис-(5-фторурацил), имеющее противоопухолевые свойства | |
| UA70747U (ru) | Тиосемикарбазоны 1,2-дизамещенных 4-хлороимидазол-5-карбальдегидов, проявляющие противотуберкулезную активность |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 MAR 2016 BY CPA GLOBAL Effective date: 20150219 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 MAR 2017 BY CPA GLOBAL Effective date: 20160219 |
|
| LAPS | Patent lapsed |